Altamira Therapeutics Ltd.

CYTO

BMG0360L1349

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets 23:00:00 11/07/2024 BST			5-day change	1st Jan Change
1.31 ^USD	-0.76%		+4.80%	-62.36%

06-20	Altamira Therapeutics Ltd. Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management	CI
05-16	Altamira Therapeutics Ltd. Elects Dominik Lysek as Member of Board of Directors	CI

Auris Medical Holding AG announced that it has received funding from Kurma Partners.

January 17, 2016

Auris Medical Holding AG (NasdaqGM:EARS) announced that it has received funding from new investor Kurma Biofund II, a fund managed by Kurma Partners on January 18, 2016.

Latest news about Altamira Therapeutics Ltd.

Altamira Therapeutics Ltd. Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management	06-20	CI
Altamira Therapeutics Ltd. Elects Dominik Lysek as Member of Board of Directors	05-16	CI
Altamira Therapeutics Ltd. Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation	05-01	CI
Altamira Therapeutics Ltd. Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal	04-24	CI
Transcript : Altamira Therapeutics Ltd., 2023 Earnings Call, Apr 10, 2024	04-10
Altamira Therapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-10	CI
Sector Update: Health Care Stocks Decline Late Afternoon	03-25	MT
Top Midday Gainers	03-25	MT
Sector Update: Health Care Stocks Softer in Afternoon Trading	03-25	MT
Altamira, Univercells Partner to Test mRNA Vaccine Delivery; Shares Surge	03-25	MT
Altamira Therapeutics Ltd. Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines	03-25	CI
Altamira Therapeutics? Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal	02-07	CI
Altamira Files Second Provisional Patent Application in Cancer Treatment; Shares Rise	01-24	MT
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment	01-24	CI
Altamira Therapeutics Back in Compliance with Nasdaq Minimum Bid Price Rules	12-29	MT
Transcript : Altamira Therapeutics Ltd. - Special Call	12-11
Altamira Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders Equity Requirement	11-29	MT
An unknown private equity investor acquired 51% stake in Altamira Medica AG from Altamira Therapeutics Ltd..	11-20	CI
Sector Update: Health Care Stocks Slipping Late Afternoon	11-17	MT
Top Midday Gainers	11-17	MT
Altamira Therapeutics to Sell 51% of Bentrio Maker for $2.3 Million	11-17	MT
An unknown private equity investor entered into a binding agreement to acquire 51% stake in Altamira Medica AG from Altamira Therapeutics Ltd. for CHF 2.04 million.	11-16	CI
Altamira Therapeutics Ltd. Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis	14/09/23	CI
Transcript : Altamira Therapeutics Ltd., H1 2023 Earnings Call, Sep 12, 2023	12/09/23
Altamira Therapeutics Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	12/09/23	CI

Chart Altamira Therapeutics Ltd.

Duration

Period

More charts

Altamira Therapeutics Ltd. is a Bermuda-based company engaged in developing ribonucleic acid (RNA)-based therapeutics for extrahepatic targets (OligoPhore/SemaPhore delivery platforms). The Company has two flagship short interfering (siRNA) programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. The delivery platform is also suited for messenger RNA (mRNA) and other types of RNA therapeutics and is focused to be leveraged via out-licensing to pharma or biotech companies. The therapeutic objective for AM-401 is to slow down KRAS driven tumor cell growth and proliferation or to stop it altogether by delivering siRNA specifically inside tumor cells for gene knock down. AM-411 is a polyplex nanoparticle delivering siRNA to inflamed tissues to target the NF-kB signaling pathway, a critical regulator of immune and inflammatory responses. Like AM-401, the drug product is based on its OligoPhore technology.

Sector

Biotechnology & Medical Research

Calendar

14/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ALTAMIRA THERAPEUTICS LTD.	-62.36%	3.71M
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	126B
REGENERON PHARMACEUTICALS, INC.	+24.67%	118B
ARGENX SE	+23.35%	27.87B
BIONTECH SE	-17.74%	20.95B
GENMAB A/S	-15.73%	16.92B
BEIGENE, LTD.	-15.21%	16.18B
NEUROCRINE BIOSCIENCES, INC.	+11.91%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.79B
SAREPTA THERAPEUTICS, INC.	+54.50%	14.08B

Bio Therapeutic Drugs

Altamira Therapeutics Ltd.

Equities

CYTO

BMG0360L1349

Biotechnology & Medical Research

Auris Medical Holding AG announced that it has received funding from Kurma Partners.

Latest news about Altamira Therapeutics Ltd.

Chart Altamira Therapeutics Ltd.

Company Profile

Income Statement Evolution

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs